Table 4 Overall survival in rectal cancer associated with neoadjuvant radiotherapy among phase III RCTs.

From: Identifying the long-term survival beneficiary of preoperative radiotherapy for rectal cancer in the TME era

Study

Treatment arm (sample size)

Total dose/daily dose (Gy)

Treatment interval time (day)

5-year OS (%)

P-value

VASOG I (1975)26

R + S (189)

20/2

14

43.4*

0.042

S (187)

  

31.6*

 

VASOG II (1986)27

R + S (126)

31.5/1.75

Immediate

50.3*

0.997

S (136)

  

49.6*

 

EORTC (1988)28

R + S (166)

34.5/2.3

11

69.1*

0.08

S (175)

  

59.1*

 

Stockholm I (1990)29

R + S (331)

25/5

7

42.0*

NA

S (348)

  

41.9*

 

Goldberg (1994)30

R + S (146)

15/5

7

40.3

0.92

S (134)

  

38.8

 

Marsh (1994)31

R + S (143)

20/5

7

30.1

0.21

S (141)

  

30.5

 

MRC II (1996)32

R + S (139)

40/2

45

31

0.1

S (140)

  

38

 

Swedish rectal cancer trial (1997)33

R + S (573)

25/5

7

58

0.004

S (574)

  

48

 

Dutch TME trial (2001)6,10

R + TME (924)

25/5

 < 10 (87%)

62.2

NA

TME (937)

  

61.9

 
  1. R radiotherapy, S surgery, TME total mesorectal excision, NA not applicable, RCTs randomized clinical trials.
  2. *Analysis of the results of patients undergoing radical surgery.
Back to article page